NCT00140712已完成1 期
A Study to Determine the Tolerability and Pharmacokinetics for Ropinirole in Paediatric / Adolescent Patients With RLS (Type 2)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- AUC(0-8), Cmax. Safety (adverse events, vital signs, ECG, laboratory parameters), Change in BP, Incidence of adverse events. Number of periodic limb movements and Number of periodic limb movements per hour (as measured by actigraphy).
研究概览
简要总结
This is a two-period dose rising study of Ropinirole Immediate Release in adolescent patients with restless legs syndrome (RLS) in order to determine the starting dose for the ropinirole titration regimen for this age group. Patients will receive two single doses unless poor tolerability is observed following the first dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adolescent subjects diagnosed with probable or definite Restless Leg Syndrome (RLS).
排除标准
- •Subjects who require RLS treatment during the daytime, suffer from other primary sleep disorders or are taking medication known to induce drowsiness, affect RLS or sleep, or to induce or treat alertness, including methylphenidate.
研究组 & 干预措施
Ropinirole
Experimental
single dose .25mg of IR formulation, .05mg of RLS controlled release
干预措施: Ropinirole Immediate Release (Drug)
结局指标
主要结局
AUC(0-8), Cmax. Safety (adverse events, vital signs, ECG, laboratory parameters), Change in BP, Incidence of adverse events. Number of periodic limb movements and Number of periodic limb movements per hour (as measured by actigraphy).
时间窗: Up to 3 years
次要结局
- PK - tmax, t1/2, For SKF-89124 and SKF-104557 - ratio of metabolite AUC:ropinirole AUC. PD - Leg movement as measured by actigraphy.(Up to 3 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)Restless Legs SyndromeNCT00225862GlaxoSmithKline140
已完成
3 期
Long-Term Safety Of Ropinirole XR In Patients With Restless Legs SyndromeRestless Legs SyndromeNCT00355641GlaxoSmithKline450
已完成
4 期
A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's DiseaseParkinson DiseaseNCT01485172GlaxoSmithKline186
已完成
4 期
A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's DiseaseParkinson DiseaseNCT01494532GlaxoSmithKline352
已完成
3 期
Ropinirole XR (Extended Release) In Patients With Restless Legs SyndromeRestless Legs SyndromeNCT00197080GlaxoSmithKline380